Topics

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

2016-03-25 06:53:23 | BioPortfolio

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Myelofibrosis

Intervention

INCB050465, INCB050465, Ruxolitinib

Location

Houston
Texas
United States

Status

Not yet recruiting

Source

Incyte Corporation

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-03-25T06:53:23-0400

Clinical Trials [178 Associated Clinical Trials listed on BioPortfolio]

An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

The purpose of this study is to assess the objective response rate with INCB050465 treatment compared to idelalisib treatment in subjects with relapsed or refractory follicular lymphoma.

A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

The purpose of this study is to evaluate the safety and efficacy of INCB050465 administered orally to participants with autoimmune hemolytic anemia (AIHA) who have decreased hemoglobin and...

A Study of INCB050465 in Primary Sjögren's Syndrome

The purpose of this study is to assess the impact of INCB050465 on the signs and symptoms of Sjögren's syndrome (SS).

A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of INCB050465 in the treatment of Japanese participants diagnosed with previously-treated B-cell lym...

A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 in Subjects With Previously Treated B-Cell Malignancies

Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, INCB05046...

PubMed Articles [73 Associated PubMed Articles listed on BioPortfolio]

Survival Outcomes in Myelofibrosis Patients Treated with Ruxolitinib: A Population-Based Cohort Study in Sweden and Norway.

To estimate survival in Swedish and Norwegian myelofibrosis (MF) patients who received ruxolitinib.

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.

After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before the receipt of ruxolitinib may pre...

Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.

Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms. During treatment, as rare conditions, leukocytosis and/or...

Post-Myelofibrosis Acute Myeloid Leukemia Effectively Treated with a Combination of Ruxolitinib and 5-Azacytidine.

Leukemic transformation is an unfavorable event emerging in a minority of patients with myelofibrosis (MF) and carrying a poor prognosis. Patients with post-MF acute myeloid leukemia (AML) may be trea...

A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).

Ruxolitinib, a selective JAK1/JAK2 inhibitor, is the current first line therapy for myelofibrosis (MF), which reduces symptomatology and splenomegaly, but does not clearly modify disease course. Panob...

Medical and Biotech [MESH] Definitions

A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.

An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.

A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.

More From BioPortfolio on "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis"

Quick Search

Searches Linking to this Trial